Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
The lipodystrophies represent a class of diseases characterized by leptin deficiency. Leptin deficiency is associated with a severe form of the metabolic syndrome characterized by dyslipidemia, insulin resistance, diabetes, and ovarian dysfunction. Metreleptin is the pharmaceutical derived product that has been approved by the Food and Drug Administration (FDA) to treat the severe metabolic abnormalities of the generalized forms of lipodystrophy. Herein we describe the properties of metreleptin, its use in patients, which includes the administration of the drug and how it may be acquired by medical professionals as well as its safety, tolerability, and properties. Finally, we speculate on future uses and development of metreleptin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of leptin in the neuroendocrine response to fasting
Ahima, R. S., Prabakaran, D., Mantzoros, C., Qu, D., Lowell, B., Maratos-Flier, E., & Flier, J. S. (1996) · Nature · doi:10.1038/382250a0 · Cited by 3,117
Effects of Recombinant Leptin Therapy in a Child with Congenital Leptin Deficiency
Farooqi, I. S., Jebb, S. A., Langmack, G., Lawrence, E., Cheetham, C. H., Prentice, A. M., Hughes, I. A., McCamish, M. A., & O'Rahilly, S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909163411204 · Cited by 1,998 · cited 1×
“The first is congenital leptin deficiency where the benefit of metreleptin therapy has been clearly demonstrated.[45,46] The second is the various forms of partial lipodystrophy.”
BackgroundFrederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA · doi:10.1001/jama.282.16.1568 · Cited by 1,422
Leptin-Replacement Therapy for Lipodystrophy
Oral, E. A., Simha, V., Ruiz, E., Andewelt, A., Premkumar, A., Snell, P., Wagner, A. J., DePaoli, A. M., Reitman, M. L., Taylor, S. I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012437 · Cited by 1,247 · cited 1×
“Garg, it immediately became apparent that metreleptin was remarkably effective in controlling metabolic parameters that had not responded to conventional therapy.[21] Further studies over the ensuing years continued to validate this initial response.”
BackgroundFarooqi, I. S., Matarese, G., Lord, G. M., Keogh, J. M., Lawrence, E., Agwu, C., Sanna, V., Jebb, S. A., Perna, F., Fontana, S., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215693 · Cited by 1,105
Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
Shimomura, I., Hammer, R. E., Ikemoto, S., Brown, M. S., & Goldstein, J. L. (1999) · Nature · doi:10.1038/43448 · Cited by 1,038 · cited 1×
“the initial beneficial effect of leptin therapy was shown in mouse models.[38] However, rodent models may not always have relevance for the human condition with respect to either the action of leptin or potential adverse effects.”
BackgroundLeptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy
Petersen, K. F., Oral, E. A., Dufour, S., Befroy, D., Ariyan, C., Yu, C., Cline, G. W., DePaoli, A. M., Taylor, S. I., Gorden, P., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215001 · Cited by 800 · cited 1×
“The next major effects of metreleptin treatment are improvement in the marked dyslipidemia, including extreme elevation of triglycerides in serum and ectopic tissues,[28] as well as insulin resistance and diabetes.”
BackgroundTargeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Chan, J. L., & Mantzoros, C. S. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66830-4 · Cited by 382 · cited 1×
“[48] Other conditions include NASH with low serum leptin levels, hypogonadotropic hypogonadism induced by extreme exercise and issues related to bone health.[49] Type 1 diabetes responds to leptin therapy in rodents,[50] but the translation of this to humans is unclear.”
BackgroundImajo, K., Fujita, K., Yoneda, M., Nozaki, Y., Ogawa, Y., Shinohara, Y., Kato, S., Mawatari, H., Shibata, W., Kitani, H., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.05.012 · Cited by 341 · cited 1×
“[40] A second example is the suggestion that leptin administration to rodents may lead to liver fibrosis,[41,42] but again this is unlikely to apply to humans.”
BackgroundLeptin therapy in insulin-deficient type I diabetes
Wang, M.-Y., Chen, L., Clark, G. O., Lee, Y., Stevens, R. D., Ilkayeva, O. R., Wenner, B. R., Bain, J. R., Charron, M. J., Newgard, C. B., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909422107 · Cited by 327
Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes
Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-4-200008150-00009 · Cited by 303
Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy†
Javor, E. D., Ghany, M. G., Cochran, E. K., Oral, E. A., DePaoli, A. M., Premkumar, A., Kleiner, D. E., & Gorden, P. (2005) · Hepatology · doi:10.1002/hep.20672 · Cited by 228 · cited 2×
“NASH, which is a fibrosing condition of the liver, may actually be improved by metreleptin therapy.[7,8] A third example is inflammatory conditions in the central nervous system of rodents that occur in the presence of leptin but not in its absence.”
BackgroundSelf-citationLong-Term Efficacy of Leptin Replacement in Patients With Generalized Lipodystrophy
Javor, E. D., Cochran, E. K., Musso, C., Young, J. R., DePaoli, A. M., & Gorden, P. (2005) · Diabetes · doi:10.2337/diabetes.54.7.1994 · Cited by 226
Self-citationLeptin in humans: lessons from translational research
Blüher, S., & Mantzoros, C. S. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.26788e · Cited by 203
McDuffie, J. R., Riggs, P. A., Calis, K. A., Freedman, R. J., Oral, E. A., DePaoli, A. M., & Yanovski, J. A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031868 · Cited by 129 · cited 1×
“The initial response to metreleptin therapy reported by patients is a sense of satiety or satiation.[26] This may result in some degree of weight loss over the first 4–6 months of therapy, but there is usually a stabilization of weight thereafter.”
BackgroundJavor, E. D., Moran, S. A., Young, J. R., Cochran, E. K., DePaoli, A. M., Oral, E. A., Turman, M. A., Blackett, P. R., Savage, D. B., O’Rahilly, S., et al. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032140 · Cited by 114 · cited 2×
“In addition, these patients may have proteinuric renal disease and the proteinuria significantly decreases with metreleptin therapy.[31,32] Using the NIH protocol, Japanese investigators demonstrated the same favorable response of metreleptin in their lipodystrophy patients, and their studies led to official approval…”
BackgroundSelf-citationChanges in body composition in patients with severe lipodystrophy after leptin replacement therapy
Moran, S. A., Patten, N., Young, J. R., Cochran, E., Sebring, N., Reynolds, J., Premkumar, A., Depaoli, A. M., Skarulis, M. C., Oral, E. A., et al. (2004) · Metabolism · doi:10.1016/j.metabol.2003.10.019 · Cited by 96
Self-citation
Cited by
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araujo-Vilar, D., Cheung, P. T., Dunger, D., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 529
Self-citationImpaired adipogenesis and dysfunctional adipose tissue in human hypertrophic obesity
Hammarstedt, A., Gogg, S., Hedjazifar, S., Nerstedt, A., & Smith, U. (2018) · Physiological Reviews · doi:10.1152/physrev.00034.2017 · Cited by 462
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak, Y. J., & Lee, S. Y. (2021) · Current Obesity Reports · doi:10.1007/s13679-020-00422-w · Cited by 343
Role of Leptin in Inflammation and Vice Versa
Pérez-Pérez, A., Sánchez-Jiménez, F., Vilariño-García, T., & Sánchez-Margalet, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165887 · Cited by 330
“Another pathophysiological leptin deficient state that can benefit from leptin replacement is lipodystrophy [173,174] with good results improving glycemic control and decreasing triglyceride levels.”
BackgroundFriedman, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci91578 · Cited by 270
Metadata
- Authors
- Meehan, C. A., Cochran, E., Kassai, A., Brown, R. J., & Gorden, P.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2015-10-14
- Volume
- 9
- Issue
- 1
- Pages
- 59-68
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2180079238
- Cited by
- 73
- References
- 19
- FWCI
- 2.68
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.